Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Apr;97(15):e0409.
doi: 10.1097/MD.0000000000010409.

Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis

Juan Zhang et al. Medicine (Baltimore). 2018 Apr.

Abstract

Background: Histamine H2 antagonists (H2RAs) have long been suggested to have beneficial effects on congestive heart failure (CHF). However, full agreement about the cardioprotective effects of H2RAs is still not reached yet. Therefore, this study aims to clarify the effects of H2RAs on myocardial function in CHF patients by meta-analysis.

Methods: Electronic databases including PubMed, Embase, and Cochrane Library were retrieved. Randomized controlled trials comparing the cardiac effects of H2RAs and placebo or other medicines were collected. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated and meta-analysis was performed using RevMan 5.3 software.

Results: A total of 10 studies (472 participants) were included in this meta-analysis. H2RAs exhibited significant negative inotropic and chronotropic effects to reduce heart rate (MD: -3.90; 95%CI: -7.07 to -0.73, P = .02). Furthermore, although H2RAs did not affect the blood pressure in health volunteers, they significantly decreased the blood pressure of CHF patients. Additionally, H2RAs were also associated with significant increase in pre-ejection period and the ratio of pre-ejection period to left ventricular ejection time.

Conclusion: In summary, these findings showed that H2RAs exerted negative inotropic and chronotropic effects to reduce heart rate and blood pressure, which, similar to beta-adrenergic receptor blockers, might decrease myocardial oxygen demand and eventually result in improvement of CHF symptoms. These data provided further evidence for the effect of H2RAs on cardiac function and novel potential strategy for treatment of CHF.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of eligible studies included in the meta-analysis.
Figure 2
Figure 2
Risk of bias graph.
Figure 3
Figure 3
Risk of bias summary.
Figure 4
Figure 4
Forest plot for comparison of heart rate between H2RAs and control group. H2RAs = Histamine H2 antagonists.
Figure 5
Figure 5
Forest plot for comparison of stroke volume between H2RAs and placebo group at 1.5, 3, and 6 hours after 1 week administration. H2RAs = Histamine H2 antagonists.
Figure 6
Figure 6
Forest plot for comparison of cardiac output between H2RAs and placebo group at 1.5, 3, and 6 hours after 1 week administration. H2RAs = Histamine H2 antagonists.
Figure 7
Figure 7
Forest plot for comparison of pre-ejection period (PEP) between H2RAs and placebo group at 1.5, 3, and 6 hours after 1 week administration. H2RAs = Histamine H2 antagonists.
Figure 8
Figure 8
Forest plot for comparison of the ratio of pre-ejection period to left ventricular ejection time (PEP/LVET) between H2RAs and placebo group at 1.5, 3, and 6 hours after 1 week administration. H2RAs = Histamine H2 antagonists.
Figure 9
Figure 9
A. Forest plot for comparison of fraction shorting (FS) between H2RAs and control group. B. Forest plot for comparison of systolic blood pressure (SBP) between H2RAs and control group. C. Forest plot for comparison of diastolic blood pressure (DBP) between H2RAs and control group. H2RAs = Histamine H2 antagonists.
Figure 10
Figure 10
Quality of evidence in GRADE. GRADE = Grading of Recommendations Assessment, Development and Evaluation.

Similar articles

Cited by

References

    1. Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 2011;54:78–85. - PubMed
    1. Maintz L, Schwarzer V, Bieber T, et al. Effects of histamine and diamine oxidase activities on pregnancy: a critical review. Hum Reprod Update 2008;14:485–95. - PubMed
    1. Patella V, Marinò I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998;97:971–8. - PubMed
    1. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived rennin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006;116:1063–70. - PMC - PubMed
    1. Shiota N, Rysä J, Kovanen PT, et al. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003;21:1935–44. - PubMed

MeSH terms

Substances